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Introduction
Rapid-cycling bipolar disorder represents a phase or
form of difﬁcult to treat and at times refractory
bipolar disorder with depression as its hallmark.
Rapid cycling is an independent predictor of inade-
quate treatment response in patients with bipolar
disorder (1–3) and is associated with greater mor-
bidity vs. non-rapid-cycling disease (4). Rapid-
cycling bipolar disorder is not well understood and
also may be missed, thus representing an important
unmet need in the treatment of bipolar I disorder
(1,4,5).
The consequences of misdiagnosis in rapid-cycling
bipolar disorder may be even greater than in non-
rapid-cycling patients given the nature of this perni-
cious variant or phase of bipolar disorder (6).
Indeed, misdiagnosis of rapid-cycling bipolar disor-
der has been associated with a twofold increase in
the rate of hospitalisation compared with patients
who were never diagnosed (7). Lifetime history of
suicide attempts was also signiﬁcantly elevated in
patients with rapid-cycling bipolar disorder who had
previously been misdiagnosed and whose clinical sit-
uation was complicated by substance use disorders,
highlighting the importance of early and accurate
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SUMMARY
Aims: Rapid-cycling bipolar disorder is difﬁcult to treat and associated with
greater morbidity than non-rapid-cycling disease. This post hoc analysis evaluated
28 patients with rapid-cycling bipolar I disorder from a 100-week, double-blind,
placebo-controlled study assessing long-term efﬁcacy, safety and tolerability of ari-
piprazole in patients with bipolar I disorder (most recently manic⁄mixed). Meth-
ods: Following ‡ 6 consecutive weeks’ stabilisation with open-label aripiprazole,
patients were randomised (1 : 1) to aripiprazole or placebo. Patients completing
26 weeks treatment without relapse could continue for a further 74 weeks. Pri-
mary end-point was time to relapse for manic, mixed or depressive symptoms,
deﬁned as discontinuation due to lack of efﬁcacy. Safety assessments included
adverse event (AE) monitoring and changes in weight and lipid, glucose and pro-
lactin levels. Results: Of the 28 patients (aripiprazole, n = 14; placebo, n = 14)
with rapid-cycling bipolar disorder, 12 (aripiprazole, n = 7; placebo, n = 5) com-
pleted the initial 26-week treatment period and three (all aripiprazole treated)
completed the 100-week, double-blind period. Time to relapse was signiﬁcantly
longer with aripiprazole vs. placebo at week 26 [log-rank p = 0.033; 26-week
hazard ratio = 0.21 (95% CI: 0.04, 1.03)] and week 100 [log-rank p = 0.017;
100-week hazard ratio = 0.18 (95% CI: 0.04, 0.88)]. The most commonly
reported AEs with aripiprazole during the 100 weeks (‡ 10% incidence and twice
placebo) were anxiety (n = 4), sinusitis (n = 4), depression (n = 3) and upper
respiratory infection (n = 3). One aripiprazole-treated patient discontinued due to
an AE (akathisia). There were no signiﬁcant between-group differences in mean
changes in weight or metabolic parameters. Conclusion: In this small, post hoc
subanalysis, aripiprazole maintained efﬁcacy and was generally well tolerated in
the long-term treatment of rapid-cycling bipolar disorder. Further research with
prospectively designed and adequately powered trials is warranted.
What’s known
• Rapid cycling is a form of difﬁcult to treat and at
times refractory bipolar disorder with depression
as a hallmark, and represents an important
unmet need in bipolar disorder treatment.
• Few data are available regarding treatment,
particularly in the long-term (> 26 weeks); this is
especially pertinent in monitoring relapse
prevention in patients with this form of bipolar
disorder.
• This study is the ﬁrst to report the long-term
effects of aripiprazole in patients with rapid
cycling.
What’s new
• This post hoc analysis looked speciﬁcally at
treatment of patients with rapid-cycling bipolar I
disorder included in a 100-week, double-blind,
placebo-controlled study to assess the long-term
efﬁcacy, safety and tolerability of aripiprazole.
Despite the small sample size, encouraging
results with aripiprazole (aripiprazole signiﬁcantly
delayed time to relapse vs. placebo) provide pilot
data that calls for larger, double-blind, placebo-
controlled investigation of aripiprazole’s efﬁcacy
and safety in the treatment of rapid-cycling
bipolar disorder.
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timely therapeutic interventions (7).
To be diagnosed with the Diagnostic and Statisti-
cal Manual of Mental Disorders, Fourth Edition
(DSM-IV) course speciﬁer of rapid cycling, patients
must have at least four mood episodes within
12 months. These episodes must be demarcated by
either a full or partial remission of at least 2 months’
duration or a switch to an episode of opposite polar-
ity. In the Systematic Treatment Enhancement Pro-
gram for Bipolar Disorder, a naturalistic study,
20% of patients were diagnosed with rapid-cycling
bipolar disorder at study entry (8).
Controversies exist, however, regarding the neces-
sary criteria for the diagnosis (particularly duration
of episodes), and the aetiology of rapid-cycling bipo-
lar disorder is poorly understood. Additionally,
patients with rapid-cycling bipolar disorder are often
excluded from clinical trials, so this lack of a full evi-
dence base is associated with little consensus on the
most appropriate treatment for these patients (5).
Previous studies with lithium, divalproex and carba-
mazepine have indicated moderate-to-marked effects
on mania, but poor-to-moderate effects in the treat-
ment of the depressed phase of rapid-cycling bipolar
disorder (5). In a prospective study with lamotrigine
in which 182 patients with rapid-cycling bipolar dis-
order were randomised to lamotrigine (n = 93) or
placebo (n = 89), there was no difference between
treatment groups in the time to additional pharma-
cotherapy (primary end-point) (9). However, sur-
vival in the study (time to any premature
discontinuation) was signiﬁcantly longer with lamo-
trigine (p = 0.036) and a greater percentage of lamo-
trigine-treated patients were stable without relapse
for 6 months of monotherapy vs. placebo-treated
patients (41% vs. 26%; p = 0.03) (9).
Attention is shifting towards the use of atypical an-
tipsychotics for the treatment of rapid-cycling bipolar
disorder, albeit via analyses of data from acute bipolar
mania or bipolar depression studies (10–14), open-
label studies with atypical antipsychotics as adjunctive
therapy (15–18) or case studies (19). Relatively fewer
data exist regarding longer-term, maintenance therapy
of rapid-cycling bipolar disorder.
Aripiprazole is pharmacologically distinct from
other atypical antipsychotics, as the efﬁcacy of this
agent is mediated through its dopamine partial agonist
activity at D2 and D3 receptors (20,21), 5-HT2A antag-
onist activity (22,23) and 5-HT1A partial agonist activ-
ity (23,24). The safety and efﬁcacy of aripiprazole have
been evaluated in both short- and longer-term studies
in patients with bipolar I mania (25–27).
A longer-term, double-blind, placebo-controlled,
26-week study showed that aripiprazole was superior
to placebo in delaying the time to relapse (28). Fur-
thermore, in the 74-week, double-blind extension of
that 26-week study (providing a total of 100 weeks’
double-blind treatment), time to relapse for the over-
all population continued to be signiﬁcantly longer
with aripiprazole vs. placebo, and aripiprazole main-
tained a good safety and tolerability proﬁle (29).
Here, we present data from a post hoc analysis of
patients with rapid-cycling bipolar I disorder who
were included in that 100-week, double-blind, pla-
cebo-controlled study to assess the long-term efﬁ-
cacy, safety and tolerability of aripiprazole in these
patients (28,29).
Methods
Study design
Details of the study methods have been described
previously (28). Brieﬂy, the original study was rando-
mised, double-blind, parallel-group and placebo-con-
trolled. During the initial stabilisation phase, patients
were treated with open-label aripiprazole (15 or
30 mg⁄day). Patients who achieved a Young Mania
Rating Scale (YMRS) total score £ 10 and a Mont-
gomery–A ˚sberg Depression Rating Scale (MADRS)
total score £ 13 over a minimum of six consecutive
weeks were eligible for double-blind treatment.
In the 100-week, prospective double-blind period,
patients were randomised (1 : 1) to receive either
aripiprazole or placebo for an initial 26-week treat-
ment period, the results of which have been reported
elsewhere (28). Patients who completed the 26-week
period without relapse were offered to continue a
further 74 weeks of double-blind treatment under
the same regimen. Results from the 100-week treat-
ment period have been reported elsewhere (29).
Entrance into the 74-week double-blind, extension
phase ended when 45 patients had relapsed. All
patients continued in a double-blind, placebo-con-
trolled fashion in the study until the last randomised
patient completed the 26-week phase. At that time,
the study was terminated, and any patient remaining
in the 74-week phase was discontinued, regardless of
the time point they had reached.
Study visits took place at randomisation (day 1 of
the double-blind phase), weekly for weeks 1–4,
biweekly for weeks 6–28, monthly for weeks 28–52
and bimonthly for weeks 52–100. All study sites
received prior Institutional Review Board
(IRB)⁄Institutional Ethics Committee (IEC) approval
before study initiation.
Patients
All patients provided written informed consent,
as required by the IRB⁄IEC. Participants met the
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IV. Diagnoses were performed using the Structured
Clinical Interview for DSM or the Mini-International
Neuropsychiatric Interview. The post hoc analyses
reported here consider only those patients diagnosed
with rapid-cycling bipolar I disorder.
Details of the inclusion and exclusion criteria are
available elsewhere (28). Brieﬂy, patients were eligible
for entry into the stabilisation phase if they had
either recently completed a 3-week, placebo-con-
trolled acute mania study of aripiprazole, if they met
eligibility criteria for an acute mania study but had
declined participation, or if they had experienced a
manic or mixed episode requiring hospitalisation
and treatment within the previous 3 months. All psy-
chotropic medications, except lorazepam and anti-
cholinergic agents, were discontinued prior to
enrolment.
Dosing schedule
Study medication was administered orally, once
daily, at approximately the same time each day. Dur-
ing the stabilisation phase, patients received open-
label aripiprazole, initially 30 mg⁄day. Dose decrease
to 15 mg⁄day was permitted at any time, depending
on tolerability. Following entry to the double-blind
phase, patients were assigned, in a double-blind
manner, to continue the dose of aripiprazole they
were taking at the end of stabilisation or to receive
placebo. Based on the investigator’s assessment of
therapeutic effect and tolerability, the aripiprazole
dose could be increased to 30 mg⁄day or decreased
to 15 mg⁄day at any time.
Efﬁcacy measures
The primary efﬁcacy end-point was the time to
relapse for a mood episode (manic, depressive or
mixed) during the initial 26-week, double-blind per-
iod of the study. Relapse was deﬁned as discontinua-
tion because of lack of efﬁcacy (indicated by hospital
admission because of a mood episode and⁄or addi-
tion to, or increase in, psychotropic medication other
than study drug for manic and⁄or depressive symp-
toms). Additional efﬁcacy measures included the
mean change from double-blind randomisation to
end-point in YMRS and MADRS total scores, and
time to relapse over the course of the additional 74-
week, double-blind extension phase.
Safety measures
Treatment-emergent adverse events (AEs; using CO-
START terminology) were collected from study com-
mencement. Vital sign measurements and changes in
body weight were also assessed. Clinical laboratory
tests included fasting measurements of triglyceride,
high-density lipoprotein cholesterol, low-density
lipoprotein cholesterol, total cholesterol, glucose and
prolactin levels.
Data analysis
The primary efﬁcacy measure – time to relapse – was
evaluated using statistical methods designed for the
time-to-event data. Kaplan–Meier survival curves
were generated for the time-to-relapse data, and
between-group differences were tested using log-rank
tests at an alpha level of 0.05 to indicate statistical
signiﬁcance. Patients who did not relapse, including
those who discontinued participation early for rea-
sons other than relapse, were censored on the date of
their last efﬁcacy evaluation or the last dose of study
medication.
Treatment differences for the incidence of clini-
cally signiﬁcant weight gain were evaluated using
Fisher’s exact test. Analysis of covariance (ANCOVA)
modelling was used to analyse change from baseline
to last observation carried forward (LOCF) end-point
in laboratory parameters. ANCOVA models included
the baseline measure as covariate and treatment
group as main effect.
Primary presentations of results from ANCOVA
and analysis of variance were the model-based esti-
mates corresponding p-values for the test of treat-
ment differences. Changes from baseline were
derived by subtracting the baseline score from that
of the LOCF end-point.
Analyses of laboratory parameters were performed
on LOCF data for the 26-week maintenance phase
and the combined 26-week maintenance and 74-week
double-blind, extension phases. LOCF values at week
26 for those patients who did not enter the 74-week
double-blind, extension phase were carried forward
to week 100.
All safety and efﬁcacy analyses were performed
using sas statistical software, version 6.12 or higher
(SAS Institute Inc., Cary, NC). For the comparison
of aripiprazole with placebo, two-tailed tests were
used to determine statistical signiﬁcance and
p £ 0.05 was considered to be statistically signiﬁcant.
Results
Patient disposition and characteristics
Detailed presentations of patient disposition and
demographics in the total population during stabili-
sation and the initial 26-week double-blind phase of
the study (28) and the entire 100-week double-blind
phase (29) are provided elsewhere.
Of the 161 patients in the total population, 28 had
a history of rapid-cycling bipolar I disorder, met the
stabilisation criteria and were randomised to aripip-
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patients [placebo, 5⁄14 (36%); aripiprazole, 7⁄14
(50%)] completed the initial 26-week, double-blind
period, and entered the 74-week, double-blind exten-
sion phase; three patients completed the full 100-
week, double-blind period [placebo, 0⁄14 (0%)
patients; aripiprazole, 3⁄14 (21%) patients] (Table 1).
The baseline demographics and characteristics in the
subgroup of patients with rapid-cycling bipolar dis-
order are shown in Table 2.
Medications
The mean ± standard deviation aripiprazole dose
during the last 7 days of the initial 26-week double-
blind phase was 25.3 ± 7.2 mg (n = 14), similar to
that during the last 7 days of the 100-week study
(23.6 ± 8.0 mg; n = 7).
Efﬁcacy
As observed in the original study in the total popula-
tion of both rapid-cycling and non-rapid-cycling
patients (28,29), time to relapse was signiﬁcantly
longer with aripiprazole vs. placebo treatment at
both 26 weeks [log-rank p = 0.033; 26-week hazard
ratio = 0.21 (95% CI: 0.04, 1.03)] and 100 weeks
[log-rank p = 0.017; 100-week hazard ratio = 0.18
(95% CI: 0.04, 0.88)] in patients with rapid-cycling
bipolar disorder (Figure 1).
The median survival time in the placebo group
was 118 days (95% CI: 14, not evaluable) at which
time approximately 45% of subjects with rapid-
cycling bipolar disorder had not yet relapsed. The
median survival time for the aripiprazole group was
not evaluable. At the time of the last relapse event in
the study period, which occurred at day 101, 81% of
aripiprazole-treated subjects with rapid-cycling bipo-
lar disorder had not yet relapsed. In the subpopula-
tion of non-rapid-cycling patients, median time to
survival in the placebo group was 203 days (95% CI:
128, 661), while the median time to survival in the
aripiprazole group was not evaluable.
The YMRS total scores increased in both groups.
The mean ± standard error (SE) increase in YMRS
total score (LOCF) was numerically smaller with ari-
piprazole vs. placebo from baseline at week 26
(+3.0 ± 2.0 vs. +6.6 ± 2.0; p = 0.213; effect size
0.506) and week 100 (+2.6 ± 2.6 vs. +9.5 ± 2.6;
p = 0.077; effect size 0.730). These results in patients
with rapid-cycling bipolar disorder were consistent
with those in the original study in the total popula-
tion of patients (28,29). In the subpopulation of
non-rapid-cycling patients, the mean ± SE increase
in YMRS total scores from baseline of the double-
blind phase to week 100 (LOCF) was signiﬁcantly
smaller with aripiprazole vs. placebo (+5.3 ± 1.4 vs.
+9.4 ± 1.4; p = 0.0374; effect size 0.369).
As observed in the original study in the total
population of patients (28,29), the MADRS total
scores increased in both treatment groups in the sub-
population of rapid-cycling patients, with no statisti-
cally signiﬁcant difference with aripiprazole vs.
placebo in the mean change in MADRS total score
(LOCF) from baseline at week 26 (+8.3 ± 3.3 vs.
+11.5 ± 3.3; p = 0.519; effect size 0.251) or week 100
(+7.7 ± 3.3 vs. +12.5 ± 3.3; p = 0.304; effect size
Table 1 Disposition of patients with rapid-cycling
bipolar disorder
Placebo,
n (%)
Aripiprazole,
n (%)
26-week, double-blind phase
Randomised 14 (100) 14 (100)
Discontinued 9 (64) 7 (50)
Lack of efﬁcacy 7 (50) 2 (14)
Adverse event 0 1 (7)
Consent withdrawal 0 2 (14)
Lost to follow-up 1 (7) 0
Other 1 (7) 2 (14)
Completed 5 (36) 7 (50)
74-week, double-blind extension phase
Entered 5 (36) 7 (50)
Discontinued 5 (36) 4 (29)
Lack of efﬁcacy 1 (7) 0
Adverse event 0 0
Consent withdrawal 0 3 (21)
Lost to follow-up 0 0
Other 4 (29) 1 (7)
Completed 0 3 (21)
Table 2 Baseline demographics and characteristics
Placebo
(n = 14)
Aripiprazole
(n = 14)
Mean ± SD age (years) 38.8 ± 11.8 37.6 ± 12.5
Gender, n (%)
Male 4 (28.6) 5 (35.7)
Female 10 (71.4) 9 (64.3)
Race, n (%)
White 12 (85.7) 9 (64.3)
Hispanic 2 (14.3) 3 (21.4)
Other 0 2 (14.3)
Mean ± SD body weight 88.7 ± 14.9 95.5 ± 18.5
Mean ± SD YMRS total score 2.0 ± 2.1 3.6 ± 3.1
Mean ± SD MADRS total score 3.5 ± 3.1 4.7 ± 4.0
SD, standard deviation; YMRS, Young Mania Rating Scale;
MADRS, Montgomery–A ˚sberg Depression Rating Scale.
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MADRS total score from baseline of the double-blind
phase to week 100 (LOCF) was not signiﬁcantly dif-
ferent between aripiprazole and placebo (+5.8 ± 1.4
vs. +7.0 ± 1.3; p = 0.5499; effect size 0.106).
Safety
In the 26-week, double-blind treatment phase, treat-
ment-emergent AEs reported in the aripiprazole
group were: anxiety (n = 4), depression (n = 3),
emotional lability (n = 2), insomnia (n = 2), ner-
vousness (n = 2), tremor (n = 2), asthenia (n = 2),
headache (n = 2), extremity pain (n = 2), neck rigid-
ity (n = 2) and dental disorder (n = 2). Treatment-
emergent AEs in the placebo group were: headache
(n = 1), anxiety (n = 1) and depression (n = 1).
Treatment-emergent AEs at week 100 are shown in
Table 3. Akathisia, sinusitis, upper respiratory infec-
tion, diarrhoea, pharyngitis, acne, urinary tract infec-
tion, ﬂu syndrome, infection and dry mouth were
additional treatment-emergent AEs that occurred as a
result of treatment with aripiprazole during the
74-week extension phase of the study (Table 3).
One patient in the aripiprazole group discontinued
because of an AE (akathisia) during the initial 26-
week, double-blind phase. No other discontinuations
because of an AE occurred during the remainder of
the 100-week study in either the placebo or aripip-
razole groups.
Mean ± SE weight change from baseline at week
26 was )3.8 ± 3.4 kg with aripiprazole (n = 11) and
+0.3 ± 4.1 kg with placebo (n = 9) (p = 0.444;
LOCF). At week 100, mean ± SE weight change from
baseline was )4.6 ± 2.7 kg with aripiprazole (n = 11)
and +0.8 ± 3.4 kg with placebo (n = 7) (p = 0.230;
LOCF).
At week 26, none of the seven patients evaluated
in the placebo group experienced clinically signiﬁcant
weight increase (‡ 7%) compared with one of 10
patients in the aripiprazole group (p = 0.588; LOCF).
During the 74-week extension phase, one patient in
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Figure 1 Time to relapse during the 100-week double-blind treatment with aripiprazole or placebo. Numbers of subjects
remaining at each censoring time point are indicated
Table 3 Treatment-emergent adverse events with an
incidence of ‡ 10% in either treatment group during
the 100-week study
Adverse event, n (%)
Placebo
(n = 14)
Aripiprazole
(n = 14)
During 26-week, double-blind phase
Anxiety 1 (7.1) 4 (28.6)
Depression 1 (7.1) 3 (21.4)
Headache 1 (7.1) 2 (14.3)
Asthenia 0 2 (14.3)
Extremity pain 0 2 (14.3)
Neck rigidity 0 2 (14.3)
Insomnia 0 2 (14.3)
Tremor 0 2 (14.3)
Emotional lability 0 2 (14.3)
Nervousness 0 2 (14.3)
Dental disorder 0 2 (14.3)
During 74-week, double-blind extension phase
Upper respiratory infection 1 (7.1) 3 (21.4)
Sinusitis 0 4 (28.6)
Infection 1 (7.1) 2 (14.3)
Akathisia 1 (7.1) 2 (14.3)
Insomnia 2 (14.3) 0
Urinary tract infection 0 2 (14.3)
Pharyngitis 0 2 (14.3)
Flu syndrome 0 2 (14.3)
Diarrhoea 0 2 (14.3)
Dry mouth 0 2 (14.3)
Acne 0 2 (14.3)
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experienced clinically signiﬁcant weight gain. In total
at week 100, one of seven placebo-treated patients
and two of 11 aripiprazole-treated patients experi-
enced clinically signiﬁcant weight gain (p = 0.472;
LOCF).
At week 100, there were no statistically signiﬁcant
changes from baseline in glucose, lipid or prolactin
levels with either aripiprazole or placebo (p > 0.05)
(Table 4). Furthermore, there were no statistically
signiﬁcant differences between aripiprazole and pla-
cebo across these metabolic parameters.
Discussion
In this post hoc analysis, aripiprazole signiﬁcantly
delayed the time to relapse in patients with rapid-
cycling bipolar I disorder (most recently manic⁄
mixed) from a 100-week, double-blind, placebo-con-
trolled study.
Of the rapid-cycling patients who were initially
stabilised on aripiprazole for six consecutive weeks
and then randomised to aripiprazole, 3⁄14 patients
completed the 100-week trial, whereas 0⁄14 placebo-
treated patients completed the trial. In comparison,
in the original study in the total population of
patients with bipolar disorder, 5⁄83 placebo-treated
and 7⁄78 aripiprazole-treated patients completed the
100-week trial (29). This high attrition rate is not
uncommon in long-term trials (13,30), but this can
limit the usefulness of long-term results, and high-
lights the difﬁculties inherent in treating bipolar
patients.
The changes in YMRS and MADRS total scores
from baseline in the aripiprazole group in this analy-
sis of patients with rapid-cycling bipolar disorder
Table 4 Mean changes in fasting clinical laboratory measures from baseline at week 100 (last observation carried
forward; safety sample)
Placebo Aripiprazole*
Total cholesterol (mg⁄dl)
N 78
Days on treatment, median (range) 302 (14–624) 281 (12–700)
Baseline (mean ± SD) 202 ± 44 172 ± 16
Week 100 (mean change ± SE) +11 ± 10 +3 ± 9
HDL-cholesterol (mg⁄dl)
N 78
Days on treatment, median (range) 302 (14–624) 281 (12–700)
Baseline (mean ± SD) 52 ± 16 47 ± 7
Week 100 (mean change ± SE) +4.2 ± 2.7 )0.04 ± 2.5
LDL-cholesterol (mg⁄dl)
N 78
Days on treatment, median (range) 302 (14–624) 281 (12–700)
Baseline (mean ± SD) 117 ± 38 100 ± 16
Week 100 (mean change ± SE) +14 ± 10 +8 ± 9
Triglycerides (mg⁄dl)
N 46
Days on treatment, median (range) 419 (118–579) 281 (56–700)
Baseline (mean ± SD) 199 ± 90 93 ± 24
Week 100 (mean change ± SE) )55 ± 30 +29 ± 23
Serum glucose (mg⁄dl)
N 46
Days on treatment, median (range) 419 (118–579) 281 (56–700)
Baseline (mean ± SD) 85 ± 7 91 ± 13
Week 100 (mean change ± SE) +4.8 ± 7.8 +3.5 ± 6.3
Prolactin (ng⁄ml)
N 11 12
Days on treatment, median (range) 42 (14–624) 275 (12–700)
Baseline (mean ± SD) 11 ± 9 13 ± 8
Week 100 (mean change ± SE) )1.6 ± 1.7 +1.3 ± 1.6
*All values p > 0.05 vs. placebo. SD, standard deviation; SE, standard error; HDL, high-density lipoprotein; LDL, low-density lipopro-
tein.
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population of aripiprazole-treated patients with bipo-
lar I disorder in the original study (28,29) and in the
subpopulation of patients with non-rapid-cycling
bipolar disorder. With aripiprazole monotherapy,
small increases in YMRS and MADRS scores were
observed over the course of the 100-week study, yet
the average total scores remained below the stability
criteria used in the open-label phase (i.e., YMRS
total £ 10 and MADRS total £ 13). Thus, aripipraz-
ole monotherapy appears to have a consistent efﬁ-
cacy proﬁle in maintaining mood stability in patients
with bipolar I disorder, including those with rapid-
cycling bipolar disorder.
Long-term aripiprazole monotherapy was generally
well tolerated in this population of rapid-cycling
patients, with the majority of treatment-emergent
AEs occurring during the 26-week, double-blind
treatment phase of the study. The effect of aripipraz-
ole on body weight in this study is of interest as
obesity is more prevalent in patients with bipolar
disorder than in the general population (31,32) and
has been noted as a correlate of poor outcome in
these patients (33). Importantly, in the current study,
aripiprazole was not associated with either signiﬁcant
weight gain or clinically relevant changes in meta-
bolic parameters, including glucose, lipid or prolactin
levels, during long-term treatment of patients with
rapid-cycling bipolar disorder.
Much insight into the safety and efﬁcacy of atypi-
cal antipsychotics for the treatment of rapid-cycling
bipolar disorder is derived from subanalyses of larger
studies in patients with bipolar disorder. Such analy-
ses have indicated the short-term efﬁcacy of quetia-
pine for the treatment of depressive symptoms (14)
and of olanzapine for the treatment of manic symp-
toms (10) in rapid-cycling patients. However, treat-
ment response in rapid-cycling patients should be
assessed over at least 4 months or three cycle lengths,
as resolution of an acute cycle is not necessarily evi-
dence that a treatment has worked (5). A previous
post hoc analysis of a 47-week, randomised, double-
blind study comparing olanzapine (5–20 mg⁄day)
with divalproex sodium (500–2500 mg⁄day) in 251
patients with bipolar mania (manic or mixed)
showed greater overall improvement with non-rapid-
cycling vs. rapid-cycling patients during long-term
treatment (12), with little difference between olanza-
pine and divalproex in the improvement in mania
(12). Most pertinent to the results of the current
study, an analysis of 179 patients with rapid-cycling
bipolar disorder from a double-blind, placebo-con-
trolled study of the safety and efﬁcacy of olanzapine
monotherapy in relapse prevention in patients with
bipolar I disorder (manic or mixed) indicated a
longer time to relapse with olanzapine vs. placebo
during up to 48-weeks maintenance therapy (13).
One prospective, randomised study investigated
lamotrigine monotherapy in patients with rapid-
cycling bipolar disorder (9). In that study, there was
no difference with lamotrigine vs. placebo in the
time to additional pharmacotherapy (primary end-
point) (9), but more patients were stable without
relapse for 6 months with lamotrigine vs. placebo
(9). Of note, the 100-week study described in the
current analysis of rapid-cycling patients is the lon-
gest double-blind, placebo-controlled study to date
investigating the efﬁcacy, tolerability and safety of
any agent other than lithium for the prevention of
relapse in the treatment of bipolar I disorder.
Interpretation of the current study is limited by
the post hoc nature of the analysis and by the small
population size (n = 28); however, the paucity of
other long-term data in patients with rapid-cycling
bipolar disorder should be acknowledged. It should
also be noted that as all patients were stabilised for
at least 6 weeks on aripiprazole prior to randomisa-
tion, the study represents an enriched population
who continued into the double-blind treatment.
Thus, the results are only applicable to those rapid-
cycling patients who respond to and are stabilised on
aripiprazole following a manic or mixed episode.
The study focused on patients with an index episode
of bipolar mania, and further studies would be
required to more speciﬁcally determine the efﬁcacy
of aripiprazole in the prophylaxis of depressive epi-
sodes in rapid-cycling bipolar disorder. This would
be of particular relevance, as patients with rapid-
cycling bipolar disorder present more frequently in
the depressed phase than the manic phase (6) and
have substantial depressive morbidity compared with
bipolar patients without rapid cycling (34).
These encouraging results with up to 100 weeks
of aripiprazole treatment call for further research
with more prospectively designed and adequately
powered trials to better investigate the efﬁcacy and
safety of long-term treatment of rapid-cycling bipo-
lar disorder. Maintenance studies that stratify
patients according to index mood polarity at study
entry (35) and protocols to assess the beneﬁts of
combination regimens (5) using atypical antipsy-
chotics such as aripiprazole would be of substantial
clinical interest.
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